// App-Quantinova.ai

SAT0013 : PIM-1 KINASE IS A MEASURABLE MEDIATOR OF CD4+ T CELL DYSREGULATION AND THERAPEUTIC TARGET IN EARLY RHEUMATOID ARTHRITIS

Researchers

Presenter

  • N. Maney

Principal Investigators

  • H. De Paula-Lemos

  • B. Barron-Millar

  • A. Mellor

  • J. D. Isaacs

  • A. Anderson

  • A. Pratt

Medical Centers

  • Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, United Kingdom

  • Musculoskeletal Services Directorate, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UNITED KINGDOM

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Cluster of Differentiation 4

  • Interleukin 6

  • T-cell receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved